EXEL Updates STELLAR-303 Trial
Exelixis provides update on the Phase 3 STELLAR-303 trial evaluating Zanzalintinib in combination with an immune checkpoint inhibitor in patients with metastatic colorectal cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.